EVALUATION OF SAFETY AND EFFECTIVENESS OF HYLAN GF-20 IN PATIENTS WITH KNEE OSTEOARTHRITIS IN REAL LIFE PRACTICE: PRELIMINARY RESULTS

Cover Page


Cite item

Full Text

Abstract

Combined conservative treatment of osteoarthritis includes intra-articular injections of hyaluronic acid. The paper presents the interim results of a prospective observational multicenter non-comparative study conducted in accordance with routine clinical practice to assess the safety and effectiveness of Hylan GF-20 in patients with knee osteoarthritis. The primary objective of the study is to assess walking and rest pain severity by WOMAC VA3.1 scale after 26 weeks and 52 weeks compared to the baseline. To date, 42 patients completed the study (71.43% women, 28.57% men), patients mean age is 59.79 years. After intraarticular injection of Hylan GF-20 patients were examined after 3, 6 and 12 months. After 3 months a positive clinical response was observed: pain severity decreased by 51.31% (p<0,001) on WOMAC A, joint stiffness decreased by 51.02% (p<0,001) on WOMAC B, daily life difficulties decreased by 42.03% (p<0,001) on WOMAC C. The same tendency was observed in the following periods. By week 52 pain severity reduced by 53.25% (p<0,001) on WOMAC A, joint stiffness by 41.63% (p<0,001) on WOMAC B, daily life difficulties -by 47.55% (p<0.001) on WOMAC C. Level of clinical response didn't correlate with the osteoarthritis stage. Therapy resulted in improvement of life quality of patients with knee osteoarthritis by 36% (p<0,001) according to the questionnaire EQ-5D. The general patients status according to physicians improved by 33.96% (p<0,001) on VAS, and by 45.91% (p<0,001) according to patients response on VAS. By week 52 of follow-up 11,90% of patients demonstrated a decrease in required concomitant therapy of osteoarthritis. Given the chronic nature of the osteoarthritis it's the most important that the therapeutic effect of Hylan GF-20 maintains until week 52. The above results confirm the efficiency of intraar-ticular injection of hyaluronic acid in patients with knee osteoarthritis especially in early disease stage.

About the authors

G. V. Kuropatkin

Samara Regional Clinical Hospital named after V.D. Seredavin, Samara

Author for correspondence.
Email: kuropatkin.gennady@gmail.com

Kuropatkin Gennady V. - head of the department of orthopedics N 1.

Ul. Tashkentskaya, 159, Samara, Russia, 443095; e-mail: kuropatkin.gennady@gmail.com

Russian Federation

References

  1. Бадокин В.В. Ревматология. Клинические лекции. М.: Литтера; 2012. 592 с.
  2. Abbott T., Altman R.D., Dimef R., Fredericson M., Vad V., Vitanzo P.Jr. Do hyaluronic acid injections delay total knee replacement surgery? Arthritis Rheum. 2013; 65: 910-911.
  3. altman R.D., Manjoo a., Fierlinger a., Niazi F., Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. Altmanet al. BMC Musculoskeletal Disorders. 2015;16:321-331.
  4. Bannuru R.R., Vaysbrot E.E., Sullivan M.C., McAlindon T. E. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43:593-599.
  5. Bellamy N., Campbell J., Welch V., Gee T.L., Bourne R., Wells G.A. Viscosupplementation for the treatment of osteoarthritis of the knee (Review). The Cochrane Collaboration. Cochrane Database Syst Rev. 2006; 9;(2):CD005321.
  6. Brander V.A., Stadler T.S. Functional improvement with hylan G-F 20 in patients with knee osteoarthritis. Phys Sportsmed. 2009;37(3):38-48.
  7. Breivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006; (10):287-333.
  8. Bruyere O., Cooper C., Pelletier J.P., Branco J., Brandi M.L., Guillemin F., Hochberg M.C., Kanis J.A., Kvien T.K., Martel-Pelletier J., Rizzoli R., Silverman S., Reginster J.Y. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthr Rheumatism. 2014;44:253-263.
  9. Chen C.P., Hsu C.C., Pei Y.C., Chen R.L., Zhou S., Shen H.C., Lin S.C., Tsai W.C. Changes of synovialfluid protein concentrations in supra-patellar. Exp Gerontol. 2014;52:30-35.
  10. Frampton J.E., Hylan GF. 20 single-injection formulation. Drugs Aging. 2010;27(1):77-85.
  11. Henrotin Y., Raman R., Richette P., Bard H., Jerosch J., Conrozier T., Chevalier X., Migliore A. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthr Rheum. 2015;45:140-149.
  12. Hochberg M.C., Altman R.D., April K.T. et al. American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthr Care Research. 2012;64(4):465-474.
  13. Jevsevar D.S. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 2013;21(9):571-576.
  14. Jevsevar D.S., Donnely P., Brown G.A., Cummins D.S. Viscosupplementation for osteoarthritis of the knee: a systematic review of the evidence. J Bone Joint Surg Am. 2015;97(24):2047-2060.
  15. Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
  16. McAlindon T.E., Bannuru R.R., Sullivan M.C. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartilage. 2014;22(3):363-388.
  17. Migliore A., Giovannangeli F., Granata M., Lagana B. Hylan G-F 20: Review of its Safety and Efficacy in the Management of Joint Pain in Osteoarthritis. Arthr Musculoskel Dis. 2010;3:55-68.
  18. pal S., Thuppal S., Reddy K.j., Avasthi S., Aggarwal A. Long-Term (1-Year) Safety and Efficacy of a Single 6-mL Injection of Hylan G-F 20 in Indian patients with Symptomatic Knee Osteoarthritis. Open Rheumat J. 2014; 8:54-68.
  19. petrella R.j., wakeford c. pain relief and improved physical function in knee osteoarthritis patients receiving ongoing hylan G-F 20, a high-molecular-weight hyaluronan, versus other treatment options: data from a large real-world longitudinal cohort in canada. Drug Des Devel Ther. 2015; 9:5633-5640.
  20. Raman R., Dutta a., Day N., Sharma H.K., Shaw c.j., johnson G.V. efficacy of Hylan G-F 20 and Sodium Hyaluronate in the treatment of osteoarthritis of the knee a prospective randomized clinical trial. Knee. 2008;15(4):318-324.
  21. Rat A.C., Baumann C., Guillemin F. National, multicentre, prospective study of quality of life in patients with osteoarthritis of the knee treated with hylane G-F 20. Clin Rheumatol. 2011;30(10):1285-1293.
  22. Raynauld j.p., Torrance G.w., Band p.A. et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthr Cartilage. 2002;10(7):506-517.
  23. Rutjes A.w.S., juni p., da costa B.R. et al. Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med. 2012;15 (3):180-191.
  24. Sakalauskiene G., Jauniskiene D. Osteoarthritis: etiology, epidemiology, impact on the individual and society and the main principles of management. Medicina (Kaunas). 2010;46(11):790-797.
  25. Waddell D.D., Joseph B. Delayed total knee replacement with HylanG-F 20. J Knee Surg. 2016;29(2): 159-168.
  26. Yan c.H., chan w.L., Yuen w.H., Yung p.S.H., Ip K.Y., Fan J.C.H., Chiu K.Y. Efficacy and safety of hylan G-F 20 injection in treatment of knee osteoarthritis in chinese patients: results of a prospective, multicentre, longitudinal study. Hong Kong MedJ. 2015;21(4):327-332.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 82474 от 10.12.2021.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies